Background-Chlamydia pneumoniae is drawing increasing attention as an agent of respiratory tract infection. Specific antibody prevalence in western countries is low in preschool children and reaches more than 50% in adults. However, little is known about the prevalence of this infection in immunocompromised subjects such as HIV-I infected patients. The aim of this study was to evaluate the seroprevalence of Chl pneumoniae in imnmunocompetent and immunocompro-
Specific antibody prevalence in western countries is low in preschool children and reaches more than 50% in adults, remaining high in old age because of Chl pneumoniae reinfection among adults.7 Little is known, however, about the prevalence of this infection in immunocompromised subjects such as HIV-I infected patients. Two recent papers reported evidence of Chl pneumoniae infection in HIV-I patients with pulmonary disease. 8 9 The aim of the present study was to evaluate Chl pneumoniae seroprevalence in immunocompetent and immunocompromised (HIV-I infected) paediatric and adult populations in Milan.
Methods Serum samples were obtained from 764 (421 men and 343 women, age range six months-81 years) asymptomatic blood donors, subjects participating in a programme for atherosclerosis primary prevention, and children screened for hepatitis B infection. Serum samples were also obtained from a large group of intravenous drug users, 96 of whom were asymptomatic but HIV-I positive (73 men, age range 18-35 years, mean (SD) 29-1 (5 2)), and 126 who were HIV-I negative (92 men, age range 18-37 years, mean (SD) 29-6 (5 8)). We also studied 50 children (23 boys, age range 8-123 months, mean (SD) 48 (10)) with vertically transmitted HIV-I infection.
All serum samples were obtained between March 1991 and September 1992. Informed consent to participate in the study was obtained from all subjects (parents for children). Percentage ofpositive results in serological t healthy subjects according to age and sex. P 
Results
The seroprevalence of Chl pneumoniae in the healthy population is shown in the figure. There was a low prevalence (1 1 %) in normal children under 10 years of age which increased progressively to 58% in adults over 70 years. Males showed a higher prevalence at all ages with the exception of children under 10 years (-12%). The greatest difference (+21 %) was observed in subjects between 50 and 59 years. The seroprevalence of Chl pneumoniae in the HIV-I infected intra- also had an IgM titre > 1:16, suggesting acute infection.
Discussion
Chlamydia pneumoniae is an emerging respiratory pathogen worldwide, causing more than 10% of community acquired pneumonias with a high seroprevalence in the adult population.7 Moreover, a possible role for this agent in low respiratory tract infections in immunocompromised patients has been suggested.89 To our knowledge, no-data on seroprevalence in HIV-I infected subjects have been reported in the literature and the epidemiology of Chl pneumoniae in Italy is unknown. We therefore studied Chl pneumoniae seroprevalence in a sample of the population of Milan, and in two groups of immunocompromised subjects represented by HIV-I infected drug users and HIV-I vertically infected children.
The microiinmunofluorescence serological test used in this study, although quite time consuming, is a specific and sensitive diagnostic method for Chl pneumoniae infection. Thom et a14 reported that isolation of Chl pneumoniae without serological evidence of acute infection is rare and occurred in only 4/1 100 of their patients. Grayston" in a large study involving more than 6000 subjects confirmed that non-specific cross reactions in the microimmunofluorescence test between Chl trachomatis and Chl pneumoniae do not occur when the test is interpreted properly for specific reactions.
Our data on population seroprevalence in the healthy population are consistent with those reported by Grayston et a!7 and show that infection is endemic in the general adult population in our area, with a similar pattern to that in other western countries. Chl pneumoniae seroprevalence in HIV-I infected subjects was significantly higher than in healthy subjects for both HIV-I vertically infected children and HIV-I infected intravenous drug users. Interestingly, in the latter group seroprevalence was also significantly higher when compared with a group of HIV-I negative intravenous drug users, suggesting that the risk factor for Chl pneumoniae infection is immunodeficiency rather than life style.
The high seroprevalence of Chl pneumoniae in HIV-I infected subjects, and the casual finding of antibody titre suggesting acute infection, together with the recent reports of clinical Chl pneumoniae infections in immunocompromised subjects8 9 confirm the potential role for this agent in the pathogenesis of respiratory tract infections in HIV-I infected subjects.
Further studies are needed to elucidate fully the pathogenetic role of Chl pneumoniae in HIV-I infected subjects, because this high antibody prevalence could be the result of either a greater rate of infection in immunocompromised subjects or a polyclonal immunoglobulin activation commonly found in HIV patients.
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